Biomarker Associations Between KL ‐6, CCL18 , SP ‐D and Progressive or Severe SSc ‐ ILD : A Systematic Review and Meta‐analysis
ACR Open Rheumatology · 2026-11 · 8 (11)
DOI: 10.1002/acr2.90121 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift ACR Open Rheumatology, online erschienen am 16.11.2026. Verfasst von Sounak Rana und 5 weiteren Autor:innen. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Systemic sclerosis (SSc) is a multiorgan rheumatologic disease in which interstitial lung disease (ILD) is a prominent, often debilitating manifestation. Noninvasive serum biomarkers ‐ Krebs von den Lungen‐6 (KL‐6), C‐C motif chemokine ligand 18 (CCL18), and surfactant protein‐D (SP‐D) ‐ have been proposed as prognostic markers in SSc‐ILD. This study aimed to determine the association between serum KL‐6, CCL18, and SP‐D levels and severe and/or progressive SSc‐ILD.
Methods
This Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA)‐concordant systematic review searched PubMed, Embase, and Cochrane for studies evaluating serum biomarker levels in SSc‐ILD patients. The primary analysis was a correlation meta‐analysis of biomarkers with pulmonary function parameters ‐ forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLco) ‐ followed by univariate meta‐regression. Secondary analyses included a regression meta‐analysis of biomarker elevation and odds ratio (OR) of progressive or severe disease, a mean difference meta‐analysis, and a sensitivity/specificity meta‐analysis.
Results
Forty‐four studies were included. KL‐6 negatively correlated with FVC% (r = −0.414) and DLco% (r = −0.402), and positively with high‐resolution computed tomography percent (HRCT%; r = 0.611). SP‐D negatively correlated with FVC% (r = −0.282) and DLco% (r = −0.347), and positively with HRCT% (r = 0.351). CCL18 showed weaker correlations. Change in KL‐6 strongly correlated with change in FVC% (r = −0.754) and predicted progressive disease (OR = 2.83). High baseline KL‐6 predicted severe (OR = 7.86) and progressive (OR = 1.87) disease; high CCL18 predicted severe disease (OR = 4.02). Both KL‐6 and SP‐D were elevated in progressive and severe ILD.
Conclusion
Serum KL‐6, SP‐D, and CCL18 are significantly associated with SSc‐ILD activity and may aid noninvasive risk stratification, though standardized thresholds remain needed.
Zitieren
APA
Rana, S., Low, C. E., Ge, G., Yong, Y. T., Tay, F. S. H., & Lim, J. W. W. (2026). Biomarker Associations Between KL ‐6, CCL18 , SP ‐D and Progressive or Severe SSc ‐ ILD : A Systematic Review and Meta‐analysis. ACR Open Rheumatology, 8(11). https://doi.org/10.1002/acr2.90121
Vancouver
Rana S, Low CE, Ge G, Yong YT, Tay FSH, Lim JWW. Biomarker Associations Between KL ‐6, CCL18 , SP ‐D and Progressive or Severe SSc ‐ ILD : A Systematic Review and Meta‐analysis. ACR Open Rheumatology. 2026;8(11). doi:10.1002/acr2.90121
BibTeX
@article{Rana2026,
author = {Rana, Sounak and Low, Chen Ee and Ge, Genevieve and Yong, Yuan Ting and Tay, Frank Sen Hee and Lim, Julian Wen Wei},
title = {Biomarker Associations Between KL ‐6, CCL18 , SP ‐D and Progressive or Severe SSc ‐ ILD : A Systematic Review and Meta‐analysis},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {11},
doi = {10.1002/acr2.90121}
}
EUVIMED